Acello designs next-generation, non-viral vectors for cell & gene therapy and green bio applications. Our proprietary ACE Foundry uses AI to design and validate vectors built to overcome the constraints that have limited the field for over a decade.
Random genomic integration by viral vectors carries a risk of secondary malignancy.
mRNA/LNP-based delivery is limited by short expression windows and dilution over cell division.
Narrow payload capacity in vectors like AAV limits gene size and count — narrowing which indications and multi-gene designs a vector can support.
Viral vector production remains complex, slow, and costly to scale.
ACE Foundry is Acello's proprietary AI-driven design platform for engineering next-generation, non-viral vectors across cell & gene therapy and green bio applications. It is purpose-built to design vectors that address safety, persistence, capacity, and manufacturability simultaneously — the four constraints that have limited the field for over a decade.
AI models design candidate vector sequences, our wet-lab infrastructure builds and validates them, and the resulting data feeds back into the next generation of designs.
Designed to minimize genomic risk
Designed for durable expression
Designed for large payloads — enabling expansion across indications
Designed for scalable, low-cost production